Pathos Communications reported first-half 2026 revenue of $7.3 million, up 14% year over year, while adjusted EBITDA ...
Pathos AI, a startup that developed artificial intelligence-enabled technologies for cancer drug research, has secured rights to two molecules whose clinical testing will proceed with a proprietary ...
Pathos Communications Plc (LSE:NEWS) founder and CEO Omar Hamdi joined Proactive's Stephen Gunnion to discuss a strong first half following the company's public listing, with double-digit growth in ...
In a single news cycle, Pathos AI announced two simultaneous drug licensing agreements worth up to $2.3 billion in combined milestones — and disclosed that it is targeting a $300 million Series E ...
Pathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERα PROTAC for ER+ Breast Cancer into the Clinic Pathos assumes responsibility for early clinical development of ...
AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and comprehensive generative artificial intelligence model for oncology. The ...
Iker Huerga, Pathos AI's chief executive. Pathos AI has added to its pipeline of cancer drugs by licensing a bispecific antibody-drug conjugate (ADC) for solid tumours from China's Alphamab in a deal ...
The average daily trading volume for Pathos Communications (NEWS) is 0. The opening price for Pathos Communications today was 27.50.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results